GlassScriptPhysician profile
Tareq Braik
NPI 1508174376
$1,205.95
in general payments reported to CMS, 2019-2025
22 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $48.67 · 2022: $65.10 · 2023: $135 · 2024: $427 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $203.26 | 2024 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $139.59 | 2022-2024 | Libtayo |
| Sirtex Medical INC | $109.63 | 2025 | Sir-Spheres Microspheres |
| Amgen INC. | $91.25 | 2019-2024 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $79.07 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $75.32 | 2019-2024 | Keytruda |
| Intuitive Surgical, INC. | $74.00 | 2025 | |
| Incyte Corporation | $72.47 | 2019-2023 | Monjuvi, Jakafi |
| Celgene Corporation | $43.70 | 2024 | Reblozyl |
| Pfizer INC. | $41.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.85 | 2019-2024 | |
| Janssen Biotech, INC. | $33.51 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $33.26 | 2019-2023 | Epkinly, Imbruvica |
| Dendreon Pharmaceuticals LLC | $32.24 | 2020 | |
| Beigene USA, INC. | $24.16 | 2024 | Brukinsa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.28 | 2024 | |
| Adaptive Biotechnologies Corporation | $20.58 | 2025 | Clonoseq |
| Mirati Therapeutics, INC. | $16.41 | 2024 | Krazati |
| Emd Serono, INC. | $16.14 | 2023 | Bavencio |
| Astellas Pharma US INC | $14.34 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tareq Braik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.